Compare AstraZeneca plc (AZN) vs MGM Resorts International (MGM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs MGM Resorts International — how do they compare? AstraZeneca plc trades at $158.71 (market cap $248.14B), while MGM Resorts International trades at $43.95 (market cap $11.10B). The key difference: AstraZeneca plc is far larger — about 22.4× MGM Resorts International's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | MGM | |
|---|---|---|
Market Cap | $248.14B | $11.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $50.69 |
52-Week Low | $147.06 | $30.72 |
Enterprise Value | $275.41B | $38.40B |
Dividend Yield | 2.01% | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
MGM Resorts International trades at $43.94, up 1.34% on the day, with a bearish technical signal from moving averages. The company reported record Q2 2026 revenue but missed earnings estimates, with net income margin at 2.4% for 2025. Recent news highlights a pending shareholder investigation into a proposed acquisition offer and expansion of BetMGM's partnerships in Canada.
The outlook is mixed: analyst consensus is a Buy with a $51.14 price target, indicating potential upside, but risks include margin pressure, high debt, and acquisition uncertainty. Earnings growth in Las Vegas and digital segments offers opportunity, yet competition and regulatory scrutiny pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
